Paper Review Records
全部论文审稿周期
21 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
70
天
Cost-effectiveness analysis of pneumococcal vaccination of at-risk and high-risk adults aged 18–64 years in Switzerland using PCV21
作者
Muloongo Simuzingili; Zinan Yi; Andrea Favre-Bulle; Thomas Mutschler; Eleana Tsoumani; Kwame Owusu-Edusei展开收起
作者单位
1. Merck & Co., Inc; 2. MSD Switzerland; 3. MSD Greece展开收起
114
天
Projected burden of bloodstream infections and the impact of molecular rapid diagnostic testing on costs and mortality in England and the United States (2025–2029): a population-level budget impact analysis
作者
James K. Karichu; Mark Pennington; Kiera Lander; Tiffeny T. Smith; Adam Thornberg展开收起
作者单位
1. Roche Molecular Systems; 2. Source Health Economics; 3. Roche Diagnostics Corporation展开收起
62
天
Societal and fiscal gains from HPV vaccination in Poland – return on investment from extending access to HPV vaccination
作者
Rafal Jaworski; Nikolaos Kotsopoulos; Marcin Czech; Mark P. Connolly; Andrew Pavelyev; Alicja Wojcik; Ugne Sabale展开收起
作者单位
1. Market Access Department, MSD; 2. Global Market Access Solutions Sàrl; 3. University of Athens; 4. Pharmacoeconomic Department, Institute of Mother and Child; 5. University Groningen; 6. Health Economic and Decision Sciences, Merck & Co., Inc; 7. Value & Implementation Outcomes Research, MSD Vilnius展开收起
41
天
Cost-effectiveness analysis of elranatamab versus physician’s choice of treatment (non–BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan
作者
Akira Yuasa; Mitsuhiro Nagano; Yoichi Kamei; Kengo Hatsuyama; Hiroyuki Matsuda; Patrick Hlavacek; Marco DiBonaventura; Kenshi Suzuki展开收起
作者单位
1. Japan Access & Value, Pfizer Japan Inc; 2. Pfizer R&D Japan G.K; 3. Real World Evidence Solutions & HEOR, IQVIA Solutions Japan G.K; 4. HTA, Value & Evidence, Pfizer Inc; 5. Myeloma/AL Amyloid Unit, Japanese Red Cross Medical Center展开收起
42
天
Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis
作者
Tendai Mugwagwa; Benjamin A. Abramoff; Siddharth Karanth; Tram Nham; Ravi K. Goyal; Elizabeth Esterberg; Gurinder S. Sidhu; Alon Yehoshua; Ruth Mokgokong展开收起
作者单位
1. Pfizer Ltd; 2. University of Pennsylvania; 3. RTI Health Solutions; 4. Pfizer Inc展开收起
53
天
Cost-effectiveness analysis of Cardioform vs. Amplatzer: concerns regarding methodological transparency and interpretation of clinical results
作者
David W. Hutton; Anne M. Ryschon; Scott Goates; Jan B. Pietzsch; Lars Søndergaard展开收起
作者单位
1. Department of Health Management and Policy, University of Michigan; 2. Wing Tech Inc; 3. Global Data Science and Analysis; 4. Abbott, CA, USA展开收起
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
